Stock ORCHPHARMA ORCHID PHARMA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News Orchid Pharma Limited Bombay S.E.

Equities

ORCHPHARMA

INE191A01027

Market Closed - Bombay S.E.
Other stock markets
 06:00:53 2024-07-16 am EDT 		5-day change 1st Jan Change
1,148 INR +2.65% Intraday chart for Orchid Pharma Limited -0.38% +60.83%
Jun. 28 Orchid Pharma Partners with Cipla to Launch Antibiotic Cefepime- Enmetazobactam in India CI
Jun. 06 Orchid Pharma Gets Indian Regulator's Nod for Enmetazobactam MT

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Orchid Pharma : Familiarisation program for Independent Directors 2023-24
PU
Orchid Pharma Partners with Cipla to Launch Antibiotic Cefepime- Enmetazobactam in India
CI
Orchid Pharma Gets Indian Regulator's Nod for Enmetazobactam
MT
Orchid Pharma Receives DCGI Approval for Its First Invented and Made-In-India Antibiotic Drug Combination of Cefepime and Enmetazobactam
CI
Transcript : Orchid Pharma Limited, Q4 2024 Earnings Call, May 24, 2024
Orchid Pharma Limited Appoints Shubha Singh as Additional Director
CI
Orchid Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024
CI
PUFE Transactions Under IBC
AQ
Orchid Pharma Limited Receives Order from Office of Assistant Commissioner Valluvarkottam Central-III Chennai Central
CI
Orchid Pharma Limited Announces Resignation of Mudit Tandon as Independent Director
CI
Orchid Pharma : Iii. Un-audited Financial Results for the quarter ended December 31, 2023 - Dec 31,2023
PU
Orchid Pharma : Un-audited Financial Results for the quarter ended June 30, 2023 - June 30,2023
PU
Orchid Pharma : Un-audited Financial Results for the quarter and half year ended September 30, 2023 - Sep 30,2023
PU
Orchid Pharma Receives United States Food and Drug Administration Approval for Its Novel Invention
CI
Transcript : Orchid Pharma Limited, Q3 2024 Earnings Call, Feb 09, 2024
Orchid Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
CI
European Medicines Agency Grants Approval for Orchid Pharma's 'Exblifep'
CI
Orchid Pharma Limited Appoints Kapil Dayya as Company Secretary & Compliance Officer
CI
Orchid Pharma Limited Announces Resignation of Marina Peter as Company Secretary and Compliance Officer
CI
Orchid Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ORCHPHARMA Stock
  4. ORCHPHARMA Stock
  5. News Orchid Pharma Limited